Sichuan Kelun Pharmaceutical Co., Ltd. Quarterly Results: Standalone & Consolidated Reports

Quarterly Results

Results Snapshot

YoYQoQ

Figures in Million

Consolidate Quarterly Results

Sep'25

Jun'25

Mar'25

Dec'24

Sep'24

Jun'24

Mar'24

Net Sales

4,193.40

4,693.43

4,389.90

5,023.64

4,961.67

5,607.68

6,219.42

Other Operating Income

0.00

Total Operating income

4,193.40

4,693.43

4,389.90

5,023.64

4,961.67

5,607.68

6,219.42

Raw Material Cost

2,355.19

2,391.53

2,334.50

2,625.32

2,574.87

2,779.30

2,812.24

Purchase of Finished goods

0.00

(Increase) / Decrease In Stocks

0.00

Employee Cost

0.00

Power Cost

0.00

Manufacturing Expenses

29.99

27.23

26.52

28.03

34.09

41.87

47.64

Selling and Distribution Expenses

1,033.94

1,101.70

899.10

1,214.42

1,043.67

1,088.94

1,455.00

Other Expenses

55.44

49.61

41.69

52.15

43.50

49.70

41.87

Total Expenditure (Excl Depreciation)

3,973.55

4,016.58

3,677.02

4,389.23

4,087.66

4,407.09

4,733.61

Operating Profit (PBDIT) excl Other Income

219.8

676.9

712.9000000000001

634.4

874

1200.6

1485.8000000000002

Other Income

65.36

57.40

73.89

87.22

4.15

82.35

134.89

Operating Profit (PBDIT)

219.64

951.93

1,086.27

889.83

1,137.57

1,497.12

1,870.51

Interest

29.99

27.23

26.52

28.03

34.09

41.87

47.64

Exceptional Items

6.28

7.51

7.63

6.22

8.21

2.53

2.94

Gross Profit (PBDT)

1,838.21

2,301.90

2,055.40

2,398.32

2,386.80

2,828.39

3,407.18

Depreciation

0.00

352.77

335.63

313.58

Profit Before Tax

195.94

579.43

714.60

532.39

776.06

1,144.20

1,512.24

Tax

100.37

190.20

113.60

138.75

135.37

310.29

338.99

Provisions and contingencies

0.00

Profit After Tax

200.04

416.38

584.24

464.96

670.82

773.92

1,026.19

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

200.04

416.38

584.24

464.96

670.82

773.92

1,026.19

Share in Profit of Associates

0.00

Minority Interest

-69.13

37.89

75.34

-24.02

34.41

156.05

259.61

Other related items

0.00

Consolidated Net Profit

130.91

454.27

659.59

440.95

705.23

929.98

1,285.80

Equity Capital

0.00

Face Value

1.0

Reserves

23,707.84

23,679.23

23,094.46

22,479.52

22,555.03

22,306.53

22,260.40

Earnings per share (EPS)

0.13

0.26

0.37

0.29

0.42

0.48

0.67

Diluted Earnings per share

0.13

0.26

0.37

0.29

0.42

0.48

0.67

Operating Profit Margin (Excl OI)

3.68%

11.54%

15.03%

9.3%

16.08%

19.64%

22.86%

Gross Profit Margin

4.67%

19.86%

24.31%

17.28%

22.41%

26.0%

29.36%

PAT Margin

4.77%

8.87%

13.31%

9.26%

13.52%

13.8%

16.5%

Public Share Holdings (%)

0.0%

Pledged Promotor Holding (%)

0.0%

Quarterly Analysis Highlights - YoY

Net Sales

YoY Growth in quarter ended Sep 2025 is -15.48% vs -0.95% in Sep 2024

Consolidate Net Profit

YoY Growth in quarter ended Sep 2025 is -81.44% vs 24.73% in Sep 2024

Operating Profit (PBDIT) excl Other Income

YoY Growth in quarter ended Sep 2025 is -86.39% vs 20.24% in Sep 2024

Interest

YoY Growth in quarter ended Sep 2025 is -12.02% vs -44.37% in Sep 2024

Operating Profit Margin (Excl OI)

YoY Growth in quarter ended Sep 2025 has fallen from Sep 2024

Compare Quarterly Results Of Sichuan Kelun Pharmaceutical Co., Ltd. With

Select Peers

Figures in Million

Consolidate Quarterly Results

Change(CNY)

Change(%)

Net Sales

4,193.40

Other Operating Income

0.00

Total Operating income

4,193.40

Raw Material Cost

2,355.19

Purchase of Finished goods

0.00

(Increase) / Decrease In Stocks

0.00

Employee Cost

0.00

Power Cost

0.00

Manufacturing Expenses

29.99

Selling and Distribution Expenses

1,033.94

Other Expenses

55.44

0.00

55.44

Total Expenditure (Excl Depreciation)

3,973.55

Operating Profit (PBDIT) excl Other Income

219.85

0.00

219.85

Other Income

65.36

Operating Profit (PBDIT)

219.64

Interest

29.99

Exceptional Items

6.28

Gross Profit (PBDT)

1,838.21

Depreciation

0.00

Profit Before Tax

195.94

Tax

100.37

Provisions and contingencies

0.00

Profit After Tax

200.04

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

200.04

Share in Profit of Associates

0.00

Minority Interest

-69.13

Other related items

0.00

Consolidated Net Profit

130.91

Equity Capital

0.00

Face Value

1.00

0.00

Reserves

23,707.84

Earnings per share (EPS)

0.13

Diluted Earnings per share

0.13

Operating Profit Margin (Excl OI)

3.68%

0.00

3.68%

Gross Profit Margin

4.67%

0.00

4.67%

PAT Margin

4.77%

0.00

4.77%

Public Share Holdings (%)

0.00

0.00%

Pledged Promotor Holding (%)

0.00

0.00%

Quarterly - Net Sales

Net Sales 419.34 Million

in Sep 2025

Figures in Million

QoQ Growth in quarter ended Sep 2025 is -10.65% vs 6.91% in Jun 2025

YoY Growth in quarter ended Sep 2025 is -15.48% vs -0.95% in Sep 2024

Quarterly - Consolidate Net Profit

Consolidate Net Profit 13.09 Million

in Sep 2025

Figures in Million

QoQ Growth in quarter ended Sep 2025 is -71.19% vs -31.12% in Jun 2025

YoY Growth in quarter ended Sep 2025 is -81.44% vs 24.73% in Sep 2024

Quarterly - Operating Profit (PBDIT)

Operating Profit (PBDIT) 15.43 Million

in Sep 2025

Figures in Million

QoQ Growth in quarter ended Sep 2025 is -82.75% vs -11.65% in Jun 2025

YoY Growth in quarter ended Sep 2025 is -86.39% vs 20.24% in Sep 2024

Quarterly - Interest

Interest 3.00 Million

in Sep 2025

Figures in Million

QoQ Growth in quarter ended Sep 2025 is 10.29% vs 2.64% in Jun 2025

YoY Growth in quarter ended Sep 2025 is -12.02% vs -44.37% in Sep 2024

Quarterly - Operating Profit Margin (Excl OI)

Operating Profit Margin (Excl OI) 3.68%

in Sep 2025

Figures in %

QoQ Growth in quarter ended Sep 2025 has fallen from Jun 2025

YoY Growth in quarter ended Sep 2025 has fallen from Sep 2024